NIH's HEAL Initiative Will Fund Your Non-Opioid Painkiller at Its Riskiest Stage: R61/R33 Analgesic Discovery, $350K a Year, September 17 Deadline

There is a specific point in the life of a drug candidate where good science goes to die. It is not the clinic, where trials are expensive but well-funded. It is not basic biology, where the NIH R01 machine hums along. It is the awkward middle — the stretch where a promising target needs a validated assay, a screening funnel, and enough medicinal chemistry to produce a real hit, but where there is no product yet to attract a venture investor and no publishable mechanism yet to attract a foundation. Pain researchers call this the valley of death. The NIH built a bridge across it, and the next span opens September 17, 2026.

That bridge is RFA-NS-25-023, "HEAL Initiative: Studies to Enable Analgesic Discovery" — a phased R61/R33 award that pays for exactly the translational work most funders avoid, aimed squarely at non-opioid, non-addictive treatments for pain. If you run a lab or a small company sitting on a novel pain target and a plausible therapeutic hypothesis, this is one of the few federal mechanisms designed to fund you before you have a lead compound. Here is how it works and how to win it.

What HEAL is, and why this NOFO exists

The Helping to End Addiction Long-term (HEAL) Initiative is the NIH's answer to the opioid crisis, and it is not a small program. Since it launched in 2018, HEAL has supported more than 1,800 research projects in all 50 states, totaling over $3 billion in investment. It is funded by Congress as distinct line items inside the budgets of two institutes — the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) — which is why it survives budget cycles that batter other programs: cutting HEAL means visibly cutting the opioid-crisis response.

HEAL's logic is a barbell. On one side, it funds addiction treatment and recovery. On the other, it funds the search for pain therapies that don't create addiction in the first place — because the fastest way to reduce opioid dependence is to give clinicians something else to prescribe. The regulatory tailwind is real: the FDA's approval of the first new non-opioid analgesic drug class in decades has proven the category can reach market, and it has made every pharma business-development team suddenly interested in non-opioid pain assets. The problem is that those teams want de-risked assets. Someone has to do the de-risking. That someone, this NOFO argues, should be you — on the government's dime.

The mechanism: a two-phase funnel with a gate in the middle

The R61/R33 is not a normal grant. It is two grants bolted together with a go/no-go milestone review between them, and understanding that structure is the whole game.

• The R61 phase funds the initial translational build-out: developing and validating the assays that define your testing funnel, then running screening efforts to identify and characterize candidate therapeutic agents. The NOFO is deliberately broad on modality — small molecules, biologics, and natural products are all in scope. This phase may run up to two years.
• The R33 phase funds the payoff work: taking your validated hits forward through preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies — the data a partner or a later-stage program will actually demand. This phase may also run up to two years.
• The combined R61/R33 project period may not exceed three years total, and budgets are capped at $350,000 in direct costs per year. Note the arithmetic: two two-year phases don't both run to their max inside a three-year ceiling, so your timeline has to be tight and your milestones have to be honest.

The transition from R61 to R33 is not automatic. NIH program staff review your R61 milestones and decide whether the project advances. This is the single most important feature of the award, and it dictates how you should write the application: the reviewers are not just asking "is this good science?" They are asking "are these milestones specific, quantitative, and falsifiable enough that we'll know in 18 months whether to keep paying?" A vague R61 aim ("we will identify promising compounds") is a proposal that dies at the gate. A concrete one ("we will deliver ≥3 chemically distinct hits with confirmed potency below a defined threshold in the validated primary assay and confirmed selectivity in the counter-screen") is a proposal that gets funded and advances.

Who should apply — and who shouldn't

This is a Clinical Trial Not Allowed NOFO, which is a useful filter. If your project involves dosing humans, this is the wrong mechanism — you want HEAL's later-stage vehicles. This award is for the discovery and early preclinical window. The strongest applicants tend to be:

• Academic labs with a validated, novel pain target and the chemistry or screening capacity (in-house or via core facilities) to build a funnel around it.
• Small biotech companies pursuing a non-opioid mechanism that is too early for SBIR reviewers to score well but too applied for a standard R01.
• Teams that can credibly claim non-addictive potential — the entire premise is "little or no addiction liability," so a proposal that doesn't address the abuse-liability profile of its mechanism head-on is missing the point of the initiative.

Both academic institutions and for-profit small businesses are eligible applicants; the R61/R33 is agnostic on that axis in a way SBIR is not. If you are a company weighing this against an SBIR route, the tradeoff is real: R61/R33 has no small-business size cap and no requirement to demonstrate commercialization intent the way an NIH SBIR proposal does, but it also won't credit your commercialization story as strongly.

Where this NOFO sits in the HEAL pipeline

"Studies to Enable Analgesic Discovery" is the front door. HEAL runs a connected set of programs through NINDS's Pain Therapeutics Development Program (PTDP) and related mechanisms, and the strategic move is to treat them as a staircase rather than a single step. Once you have hits and preliminary efficacy from an R61/R33, the natural next rung is HEAL's Non-addictive Analgesic Therapeutics Development (UG3/UH3) track — a later-stage, milestone-driven cooperative agreement for small molecules and biologics headed toward IND-enabling work. Writing your R61/R33 with that next award explicitly in view — generating exactly the data a UG3/UH3 reviewer will want — is how you turn a three-year grant into a decade-long, non-dilutive funding relationship with the NIH.

The deadline discipline

The recurring application due dates for this NOFO fall on a predictable cadence — mid-January, mid-May, mid-September — and the next one is September 17, 2026. For a phased, milestone-heavy application, that window is tighter than it looks. You need a validated (or near-validated) primary assay concept, a defensible target rationale with abuse-liability framing, letters from any core facilities or chemistry collaborators, and a milestone table that a program officer could administer with a stopwatch. Start the Just-in-Time and registration housekeeping now — NIH requires active SAM.gov, eRA Commons, and Grants.gov registrations, and those routinely take longer than first-time applicants expect.

The broader point: federal pain-therapeutics money is one of the few research lines with genuine bipartisan durability, a regulatory pathway that now demonstrably works, and a funding mechanism built specifically to carry projects across the valley where private capital refuses to go. If your science lives in that valley, the September window is the one to hit.

Granted tracks HEAL, NINDS, and NIDA funding opportunities alongside every open federal and foundation source. Search the full database to match your pain-therapeutics program to the right mechanism and deadline.